NR- 1-400

rom the	100	PATENT COOPE	RATION TRE	WAILHG	
TERNATIONAL SEARCHING AUTHORITY To:				DSG IFOR	
LARS H. GENIESER VENABLE LLP				101	
P.O. BOX 34385 WASHINGTON, DC 20043-9998			WR	LITTEN OPINION OF THE	
WASIII101011, DC 2004	3-7776		INTERNATIO	ONAL SEARCHING AUTHORITY	
		SEP	<b>5</b> 2008	(PCT Rule 43bis.1)	
		. **	Date of mailing (day/month/year)		
Applicant's or agent's file re	ference		FOR FURTHER		
58086-242185				See paragraph 2 below	
International application No.		International filing date	(day/month/year)	Priority date (day/month/year)	
PCT/US07/07485		27 March 2007 (27.03.2)		27 March 2006 (27.03.2006)	
International Patent Classific	. ,	or both national classificat	ion and IPC		
IPC: Please See Continu USPC: 514/341,385:548/3		16.7;546/272.7,274.1,274.	4		
Applicant	,	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
MICHAEL JUNG					
1. This opinion contains in	dications rela	ating to the following item	s:		
Box No. 1	Basis of the opinion				
Box No. 11	Priority				
Box No. 111	Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
Box No. 1V	Lack of unity of invention				
Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Box No. VI	Certain documents cited				
Box No. VII	Certain defects in the international application				
Box No. VIII	VIII Certain observations on the international application				
2. FURTHER ACTION	1				
International Preliminar Authority other than thi	y Examinin s one to be t	Authority ("IPEA") ex	cept that this does IPEA has notified th	be considered to be a written opinion of the not apply where the applicant chooses an e International Bureau under Rule 66.1bis(b) red.	
If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailling of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later. For further options, see Form PCT/ISA/220.					

3. For further details, see notes to Form PCT/ISA/220.

Name and mailing address of the ISA/US Date of completion of this opinion Authorized officer Mail Stop PCT, Attn: ISA/US Commissioner for Patents Jason M. Nolan, Ph.D. 27 August 2008 (27.08.2008) P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (571) 273-3201 Telephone No. (571) 272-4356

Form PCT/ISA/237 (cover sheet) (April 2007)

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No.	
PCT/US07/07485	

Box No. I Basis of this opinion						
1. With	regard to the language, this opinion has been established on the basis of:					
$\boxtimes$	the international application in the language in which it was filed					
	a translation of the international application into, which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).					
2. 🔲	This opinion has been established taking into account the rectification of an obvious mistake authorized by or notified to th Authority under Rule 91 (Rule 43bis.1(a))					
<ol> <li>With establ</li> </ol>	regard to any nucleotide and/or amino acid sequence disclosed in the international application, this opinion has been ished on the basis of:					
a.	type of material					
	a sequence listing					
	table(s) related to the sequence listing					
b.	format of material					
	on paper					
	in electronic form					
c.	time of filing/furnishing					
	contained in the international application as filed.					
	filed together with the international application in electronic form.					
	furnished subsequently to this Authority for the purposes of search.					
4. 🗌	In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.					
5. Additi	onal comments:					
	<b>b</b>					
		١				
		١				
	•	۱				
		I				

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US07/07485

Box No. V Reasoned statement under Rule 43 bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement 1. Statement Novelty (N) Claims 3.4.11.13.16.37 YES Claims 1,2,5-10,12,14,15,17-36 NO Inventive step (IS) Claims 3,4,11,13,16,37 YES Claims 1,2,5-10,12,14,15 and 17-36 NO Claims 1-37 Industrial applicability (IA) YES Claims NONE NO 2. Citations and explanations: Claims 1, 5, 7-10, 12, & 17-36 lack novelty under PCT Article 33(2) as being anticipated by SUN et al. because the publication by SUN et al. discloses compounds which anticipate the instant formula II wherein A & B = 0; Het = pyridine; R1 & R2 form a substituted heterocyclic ring; R3 = H; R4 = CN; R5 = Cl; and R6 & R7 = H. Further, the compounds of SUN et al. are androgen receptors useful for the treatment of diseases acting via said receptor. Claims 1, 2, 6-9, 12, 14, 15, & 17-36 lack novelty under PCT Article 33(2) as being anticipated by STROBEL et al. because the publication by STROBEL et al. discloses compounds which anticipate the instant formula II wherein A & B = O; Het = pyridine or 5membered rings with N & S or multiple N; R1 = substituted alkyl; R2 = H or alkyl; R3 = alkyl. Said compounds are useful for treating cancer. Claims 1, 7-9, 12, & 17-36 lack novelty under PCT Article 33(2) as being anticipated by MOON et al. because shown the publication by MOON et al. discloses compounds that anticipate the instant formula II wherein A = S; B = O; Het = pyridine; R3 = H; and R1 & R2 form a substituted heterocyclic ring. Said compounds are useful for treating cancer.

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/US07/07485

Supplemental Box In case the space in any of the preceding boxes is not sufficient.						
Continuation of IPC: A61K 31/4166( 2006.01),31/4178( 2006.01),31/4439( 2006.01);C07D 401/04( 2006.01),233/86( 2006.01)						
	•					

Form PCT/ISA/237 (Supplemental Box) (April 2007)